CLIC3 interacts with NAT10 to inhibit N4-acetylcytidine modification of p21 mRNA and promote bladder cancer progression

Yujun Shuai,Hui Zhang,Changhao Liu,Junting Wang,Yangkai Jiang,Jiayin Sun,Xincheng Gao,Xiaochen Bo,Xingyuan Xiao,Xin Liao,Chao Huang,Hebing Chen,Guosong Jiang
DOI: https://doi.org/10.1038/s41419-023-06373-z
2024-01-06
Cell Death and Disease
Abstract:Chromatin accessibility plays important roles in revealing the regulatory networks of gene expression, while its application in bladder cancer is yet to be fully elucidated. Chloride intracellular channel 3 (CLIC3) protein has been reported to be associated with the progression of some tumors, whereas the specific mechanism of CLIC3 in tumor remains unclear. Here, we screened for key genes in bladder cancer through the identification of transcription factor binding site clustered region (TFCR) on the basis of chromatin accessibility and TF motif. CLIC3 was identified by joint profiling of chromatin accessibility data with TCGA database. Clinically, CLIC3 expression was significantly elevated in bladder cancer and was negatively correlated with patient survival. CLIC3 promoted the proliferation of bladder cancer cells by reducing p21 expression in vitro and in vivo. Mechanistically, CLIC3 interacted with NAT10 and inhibited the function of NAT10, resulting in the downregulation of ac4C modification and stability of p21 mRNA. Overall, these findings uncover an novel mechanism of mRNA ac4C modification and CLIC3 may act as a potential therapeutic target for bladder cancer.
cell biology
What problem does this paper attempt to address?
This paper mainly discusses the role of chloride intracellular channel protein 3 (CLIC3) in the progression of bladder cancer. The study identified key genes by integrating chromatin accessibility data and transcription factor binding site cluster regions (TFCR), and found that CLIC3 was upregulated in bladder cancer tissues and negatively correlated with patient survival rate. CLIC3 inhibits N4-acetylcytidine (ac4C) modification by interacting with NAT10, thereby reducing the stability and expression of p21 mRNA and promoting the proliferation of bladder cancer cells. NAT10 is a known ac4C modification enzyme, and inhibition of its function leads to degradation of p21 mRNA, affecting tumor progression. Therefore, CLIC3 may serve as a potential therapeutic target for bladder cancer.